Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients.

@article{Gneiss2006DifferingIP,
  title={Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients.},
  author={Claudia Gneiss and Patrick G Tripp and F Reichartseder and Robert Egg and Rainer Ehling and Andreas Lutterotti and Michael Khalil and Bettina Kuenz and Irmgard Mayringer and Markus Reindl and Thomas F H Berger and Florian Deisenhammer},
  journal={Multiple sclerosis},
  year={2006},
  volume={12 6},
  pages={731-7}
}
Interferon beta (IFNbeta) is a first-line therapy for multiple sclerosis (MS). However, some patients experience a decline in efficacy with continued therapy due to the development of anti-IFNbeta neutralizing antibodies (NAb). We investigated the frequency of NAb cross-sectionally in 846 MS patients who were receiving IFNbeta-1b, IFNbeta-1a im, or IFNbeta-1a sc. The frequency of NAb in patients receiving IFNbeta-1a im was lower (5%) than in patients treated with any other form of IFNbeta (22… CONTINUE READING

From This Paper

Topics from this paper.
20 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 20 extracted citations

Similar Papers

Loading similar papers…